Phase I, open-label study of pasireotide in patients with <i>BRAF-</i>wild type and <i>NRAS</i>-wild type, unresectable and/or metastatic melanoma. by Dummer, R. et al.
  1Dummer R, et al. ESMO Open 2018;3:e000388. doi:10.1136/esmoopen-2018-000388
Open access 
Phase I, open-label study of pasireotide 
in patients with BRAF-wild type and 
NRAS-wild type, unresectable and/or 
metastatic melanoma
Reinhard Dummer,1 Olivier Michielin,2 Mirjam Chantal Nägeli,1 
Simone M. Goldinger,1 Federico Campigotto,3 Ulrike Kriemler-Krahn,4 
Herbert Schmid,4 Alberto Pedroncelli,4 Sara Micaletto,1 Dirk Schadendorf5 
Original research
 ► Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
esmoopen- 2018- 000388).
To cite: Dummer R, Michielin O, 
Nägeli MC, et al. Phase I, 
open-label study of pasireotide 
in patients with BRAF-wild 
type and NRAS-wild type, 
unresectable and/or metastatic 
melanoma. ESMO Open 
2018;3:e000388. doi:10.1136/
esmoopen-2018-000388
Received 25 April 2018
Revised 25 May 2018
Accepted 26 May 2018
1Department of Dermatology, 
University Hospital Zurich, 
Zurich, Switzerland
2Multidisciplinary Oncology 
Center, Lausanne University 
Hospital (CHUV), Lausanne, 
Switzerland
3Global Medical Affairs, Novartis 
Pharmaceuticals Corporation, 
East Hanover, New Jersey, USA
4Clinical Development, Novartis 
Pharma AG, Basel, Switzerland
5Department of Dermatology, 
University Hospital Essen, 
Essen, Germany & German 
Cancer Consortium, Heidelberg, 
Germany
Correspondence to
Professor Reinhard 
Dummer, Department of 
DermatologyUniversity Hospital 
Zurich Zurich Switzerland ;  
reinhard. dummer@ usz. ch
© European Society for 
Medical Oncology 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. Published 
by BMJ.
AbstrAct
Introduction Somatostatin analogues exert antitumour 
activity via direct and indirect mechanisms. The present 
study was designed to assess the safety and efficacy 
of pasireotide in patients with BRAF-wild type (WT) and 
NRAS-WT metastatic melanoma.
Patients and methods Patients with unresectable and/
or metastatic melanoma or Merkel cell carcinoma were 
eligible. Pasireotide was administered at different doses 
for ≤8 weeks in dose-escalation phase, followed by long-
acting pasireotide 80 mg or lower dose in case of toxicity 
in follow-up phase up to six additional months. Primary 
endpoint was safety in the first 8 weeks of dose-escalation 
phase.
Results The study was terminated early due to slow 
recruitment. Of the 10 patients with metastatic melanoma 
enrolled, only four reached the high dose level: two 
patients reached 3600 µg in dose-escalation and follow-
up phases and two patients reached 3600 µg in dose-
escalation and long-acting pasireotide 80 mg in follow-up 
phases and were stable for >5 months. Most common 
adverse events (AEs) during dose-escalation phase in 
≥2 patients (20%) were: diarrhoea (50%), nausea (50%), 
fatigue (20%), hyperglycaemia (20%), hypophosphatemia 
(20%), chills (20%) and tumour pain (20%). Grade 3 or 
4 study drug-related AEs were diarrhoea and nausea, 
reported in one patient. Partial response was documented 
in one patient and stable disease in another.
Conclusions Pasireotide was well tolerated, and safety 
results were similar to those previously reported in other 
indications. Further studies are needed to evaluate its 
antitumour activity alone and in combination with other 
drugs in melanoma.
IntRoduCtIon
Melanoma is the most aggressive and some-
times treatment-resistant form of skin cancer. 
BRAF-wild type (WT) and NRAS-WT tumours 
are observed in approximately 28%–32% 
of melanomas.1 2 The constitutive activa-
tion of the mitogen-activated protein kinase 
(MAPK) signalling pathway in BRAF-WT and 
NRAS-WT melanoma may be due to the loss 
of function mutations and deletions in NF1 
(a tumour suppressor gene encoding the RAS 
GTPase-activating protein). NF1 mutations 
are identified in up to 70% of BRAF-WT and 
Key questions
What is already known about this subject?
 ► Until now, the treatment options for patients with 
BRAF-wild type (WT) and NRAS-WT melanoma are 
limited.
 ► Mitogen-activated protein kinase (MAPK) and PI3K 
pathways are the major signalling pathways in mel-
anoma, which regulate cell growth, proliferation, 
survival and transformation. Somatostatin recep-
tors (SSTRs) and insulin growth factor receptors are 
overexpressed in human melanoma cells and are 
upstream of the Ras/MAPK signalling pathway.
 ► Somatostatin analogues (such as pasireotide) exert 
antitumour activity in different tumours like pituitary, 
prostate, gastric, lung, pancreas, colorectal or thy-
roid origin, both via direct (mediated through SSTRs) 
and indirect mechanisms (insulin-like growth factor 
1 (IGF-1) signalling pathway).
What does this study add?
 ► This is the first phase I study to assess the safety and 
efficacy of pasireotide in patients with unresectable 
and metastatic BRAF-WT and NRAS-WT melanoma.
 ► We observed that pasireotide was well tolerated, 
and the safety profile was similar to the prior reports 
in other indications.
 ► Of 10 patients included in the study, stable disease 
and partial response were observed in one patient 
each.
How might this impact on clinical practice?
 ► Though the antitumour activity in these late-staged 
patients was limited, pasireotide could be potentially 
used in combination with other therapeutic agents in 
the treatment of patients with BRAF-WT and NRAS-
WT melanoma.
 ► Further prospective randomised studies are war-
ranted to evaluate the efficacy of pasireotide in 
BRAF-WT and NRAS-WT melanoma.
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NRAS-WT melanomas.3 The other activating mutations 
of KIT, amplification of KIT, CCND1 and TERT are also 
observed in this population.4 5 
Somatostatin and its analogues (SSAs) bind to soma-
tostatin receptors (SSTR)1–5 with variable affinities 
and may directly inhibit the cell growth by the inhibi-
tion of cell proliferation through the cell cycle control 
and induction of apoptosis.6 The data from preclinical 
and clinical studies demonstrate that SSAs exert antitu-
mour effects in different tumour types including those 
of pituitary, prostate, gastric, lung, pancreas, colorectal 
or thyroid origin.7–11 One or more subtypes of SSTRs 
are also highly expressed in melanoma cell lines12 and 
tumour samples obtained from patients with melanoma 
(with some subtypes being more abundant than other 
subtypes [SSTR1>SSTR2>SSTR3>SSTR4>SSTR5]).
13 The 
insulin-like growth factor receptors (IGFRs) are also 
overexpressed in human melanoma cells, and the IGF-1 
signalling pathway via IGF-1R is shown to play a key role 
in melanoma progression.14 15
Pasireotide, a second-generation SSA, has a broader 
affinity for SSTRs compared with the first-generation 
SSAs, octreotide and lanreotide. The binding affinity of 
pasireotide is highest for SSTR5 (IC50: 0.16±0.01 nmol/L) 
and SSTR2 (IC50: 1±0.1 nmol/L) with moderate affinity 
to SSTR3 (IC50: 1.5±0.3 nmol/L) and SSTR1 (IC50: 
9.3±0.1 nmol/L), and low affinity towards SSTR4 recep-
tors (IC50: >100 nmol/L).
16 Pasireotide also inhibits IGF-1 
plasma levels more effectively than octreotide.17 Pasir-
eotide demonstrated antitumour activity in phase 3 clin-
ical studies by significantly reducing growth hormone 
(GH) and IGF-1 levels and shrinking tumours in patients 
with acromegaly.18 Long-acting pasireotide showed a 
trend towards higher tumour control rate at month 6 
(although not statistically significant) and was associated 
with a longer progression-free survival than long-acting 
octreotide in patients with metastatic neuroendocrine 
tumours (NETs).19 In a recent phase 2 study in patients 
with lung NETs, pasireotide alone had significant antitu-
mour efficacy of the same magnitude as everolimus, and 
the combination of both compounds resulted in a poten-
tiation of the antitumour effect.20
Therefore, SSTRs and the IGF-1 signalling path-
ways, which are upstream of the Ras/MAPK signalling 
pathway,21 may potentially be targeted using pasireotide 
in BRAF-WT and NRAS-WT melanoma. In the present 
study, we assessed the safety profile and the preliminary 
antitumo activity of pasireotide in patients with BRAF-WT 
and NRAS-WT metastatic melanoma.
PatIents and metHods
Adult patients (aged ≥18 years) with histologically/
cytologically confirmed, unresectable (stage III) and/
or metastatic (stage IV) melanoma or metastatic Merkel 
cell carcinoma (MCC) excluding patients with BRAF and 
NRAS mutations were eligible. Only patients with meas-
urable disease according to Response Evaluation Criteria 
in Solid Tumour version 1 (RECIST 1.0) and the pres-
ence of ≥1 lesion suitable for standardised uptake value 
measurements on 18-fluorodeoxyglucose positron emis-
sion tomography (18-FDG-PET) were included in the 
study. The other key eligibility criteria included Eastern 
Cooperative Oncology Group performance status of 0 or 
1 and adequate organ function. Patients with unknown 
BRAF-mutation or NRAS-mutation status, primary uveal 
melanoma, prior treatment with SSA or hypersensitivity 
to SSA and those receiving >3 prior lines of systemic 
therapy, prior radiotherapy, an investigational drug or 
any antineoplastic therapy within 4 weeks prior to base-
line were excluded from the study.
The study was conducted in accordance with US Food 
and Drug Administration (USFDA) guidelines, Good Clin-
ical Practice, the Declaration of Helsinki and applicable 
local health authority requirements. All patients provided 
written informed consent. The study was approved by the 
institutional review boards and registered on  Clinical-
trials. gov as NCT01652547.
study design
This was an open-label, single-arm, multicentre, intrapa-
tient, dose-escalation, phase I study to evaluate the prelim-
inary safety, pharmacokinetics (PK) and antitumour 
activity of pasireotide (SOM230) subcutaneous (SC) at 
doses of 300 µg, 600 µg, 900 µg and 1200 µg three times 
a day in patients with metastatic melanoma or metastatic 
MCC. As per the protocol amendment 4, patients were 
allowed to switch to 80 mg long-acting pasireotide intra-
muscular every 28 days (or a lower dose in case of toxicity) 
for an additional 6 months, during the follow-up phase 
(online supplementary figure 1). It is to be noted that 
this study was not designed to determine the maximum 
tolerated dose (MTD). The maximum allowable dose in 
this study was 1200 µg three times a day (total daily dose 
of 3600 µg, which is still below the MTD for the SC formu-
lation in healthy volunteers 1950 µg twice a day=total daily 
dose of 3900 µg).
assessments
The primary objective of the study was to assess the safety 
profile of pasireotide SC during the 8-week dose-esca-
lation phase. The secondary objectives included the 
assessment of safety at study completion, disease control 
rate (DCR; defined as the proportion of patients with a 
best overall response (ORR) of complete response (CR) 
or partial response (PR) or stable disease), PK and the 
effect of pasireotide on melanoma response biomarkers 
(S100b, melanoma-inhibitory activity (MIA)) and treat-
ment response and/or secretion biomarkers over time.
Safety was monitored by clinical assessments including 
laboratory evaluations, ECGs, vitals, physical examina-
tion, gall bladder ultrasound, and recording adverse 
events (AEs) through the electronic case report form 
at each visit. The site investigator used RECIST version 
1.0,22 assisted by the CT or MRI, to assess ORR, defined 
as the proportion of patients with a best overall CR or PR, 
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measured on days 57, 113, 169 and at the end of treat-
ment. In addition, ORR was also assessed using adapted 
European Organization for Research and Treatment of 
Cancer criteria by 18-FDG-PET on days 29 and 57. The 
serum samples were estimated for PK parameters on days 
1 and 8 during the four cycles of the dose-escalation phase 
and at monthly visits during the follow-up phase using 
non-compartmental analysis by Phoenix (V.6.3, Pharsight, 
Mountain View, California, USA). Pharmacokinetic 
parameters included pasireotide maximum/minimum 
concentration on days 1 and 8 for each cycle (Cmax and 
Cmin) and area under the curve from 0 to 2 hours (AUC0–
2h) at steady state. The secretion biomarkers assessed over 
time included S100b and MIA, IGF-1, IGF-2, IGF-binding 
protein 2 (IGFBP2) and IGFBP3.
statistical analysis
A sample size of 18 eligible patients was considered to 
be sufficient to assess the safety of pasireotide SC in this 
patient population. With 18 patients, there was an 85% 
of probability of detecting an AE with a 10% incidence 
rate. However, due to the slow recruitment and change in 
the treatment landscape, this study was terminated early 
without full enrolment of 18 patients according to the 
planned sample size. Safety, PK and efficacy results were 
presented for the 10 enrolled patients.
Patients who received at least 1 dose of study medica-
tion and had at least one post-baseline safety assessment 
were used for all safety analyses. Patients who received at 
least 1 dose of study drug were used for all efficacy anal-
yses. The study endpoints were reported according to 
the following two study phases: the dose-escalation phase 
and the overall phase. The patient characteristics, safety, 
efficacy and laboratory endpoints were summarised with 
descriptive statistics and 95% CI as appropriate. The data 
were analysed using SASV.9.3.
Results
Patient characteristics
Ten patients with BRAF-WT and NRAS-WT melanoma 
received the pasireotide treatment. Patients with MCC 
could not be recruited. All the patients were Caucasians 
with the median age of 71.5 years (range, 60–77 years); 
80% of the patients were males. All the patients (unre-
sectable stage III/IV melanoma) were heavily pretreated, 
underwent prior surgical treatment for their disease 
and received prior antineoplastic therapies as shown in 
table 1.
The patient disposition is illustrated in online supple-
mentary figure 2. The safety, efficacy and PK anal-
yses included those 10 patients who were treated with 
pasireotide.
Among the 10 patients, five completed the dose-es-
calation phase; the follow-up phase was reduced from 
6 months to 3 months after the decision to terminate 
the study early, and the patients were offered to receive 
further pasireotide treatment in a rollover study. Three of 
those five patients (30%) completed the follow-up phase. 
One patient completed the study as per protocol: 8 weeks 
of dose-escalation phase and an additional 6-month 
follow-up. Two of those three patients (20%) completed 
the follow-up phase receiving 80 mg long-acting pasir-
eotide for at least 3 months. Three of the five patients 
received pasireotide SC three times a day.
safety
Dose-escalation phase
The median duration of pasireotide exposure in this 
phase was 6.7 weeks (range, 1.6–8.1 weeks); one patient 
was exposed to pasireotide SC for >8 weeks in the 
dose-escalation phase. The most commonly reported 
AEs (incidence ≥20%) were diarrhoea (50%), nausea 
(50%), fatigue (20%), hyperglycaemia (20%), hypophos-
phatemia (20%), tumour pain (20%) and chills (20%) 
(table 2). The most frequently reported study drug-re-
lated AEs (incidence ≥20%) were diarrhoea (50%), 
nausea (50%), hyperglycaemia (20%) and fatigue 
(20%). Grade 3 or 4 study drug-related AEs (diarrhoea 
and nausea) were observed in one patient. Study drug-re-
lated serious AEs (SAEs) were nausea, vomiting and diar-
rhoea in one patient, which occurred at pasireotide SC 
300 µg.
One patient died due to disease progression 5 days after 
the premature termination of study treatment, and one 
patient died due to disease progression 12 days after the 
withdrawal of consent. Both patients were treated only for 
a very short period of time (16 days and 11 days of treat-
ment, respectively).
Table 1 Baseline characteristics
Baseline characteristic
All patients, 
n=10
Age (years)
Median (range) 71.5 (60–77)
Gender, n (%)
Male 8 (80.0)
Female 2 (20.0)
Race, n (%)
Caucasian 10 (100.0)
Ethnicity, n (%)
Other 10 (100.0)
Baseline weight (kg)
Mean (SD) 77.0 (13.4)
Height (cm)
Mean (SD) 170.6 (8.7)
Prior antineoplastic therapy, n (%)
Prior surgery 10 (100)
Prior radiotherapy 4 (40)
Prior anticancer medications 6 (60)
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Overall safety
Overall, the median duration of exposure to pasireotide 
SC was 7.6 weeks (range, 1.6–32.1 weeks); one patient 
was exposed to pasireotide SC for >28 weeks. Of the five 
patients in the follow-up phase, one patient received 
pasireotide SC and completed the follow-up phase, 
two discontinued the pasireotide SC treatment, and 
two received long-acting pasireotide 80 mg for at least 
3 months in the follow-up phase. The most commonly 
reported AEs (incidence ≥20%) were diarrhoea (50%), 
nausea (50%), fatigue (30%), hyperglycaemia (30%), 
hypophosphatemia (30%), chills (20%), tumour pain 
(20%) and decreased weight (20%) (table 3). Study 
drug-related AEs were reported in 80% of patients, and 
they included diarrhoea (50%), nausea (50%), hyper-
glycaemia (30%), fatigue (20%), hypophosphatemia 
(20%) and weight decrease (20%). The hyperglycaemia 
occurring in two patients was managed by concomitant 
medications including gliclazide and metformin hydro-
chloride. Grade 3 or 4 drug-related AEs were observed 
in 20% of patients (diarrhoea and nausea in one patient, 
and hypophosphatemia in one patient). SAEs, suspected 
to be study drug related, included nausea, vomiting and 
diarrhoea in one patient.
efficacy
Among the total 10 patients included in the study, the 
best ORR (defined as PR or better) was observed in one 
(10%) patient (95% CI 0.3 to 44.5), and best overall 
DCR (defined as stable disease or better) was observed 
in two (20%) patients (95% CI 2.5 to 55.6), both by CT 
or MRI and 18-FDG-PET. Stable disease and PR were 
observed in one patient each. The best ORR for patients 
with the measurable disease at baseline is presented in 
(online supplementary table 1). Four patients reached 
high dosing (two patients reached 3600 µg in the 
dose-escalation phase and the follow-up phase, and two 
patients reached 3600 µg in the dose-escalation phase 
and long-acting pasireotide 80 mg in the follow-up phase 
and were stable for more than 5 months). One patient 
achieved stable disease in target lesions (patient number 
3). However, it was not considered to be stable disease 
by RECIST criteria due to the worsening of one of the 
non-target lesions, and the response was considered as 
progressive disease (PD).
Pharmacokinetics
The mean plasma concentration of pasireotide versus 
time profiles on day 8 suggested that the AUC0–2h, Cmax 
and Cmin increased with the increasing dose. The accumu-
lation ratio of AUC0–2h was 147% for 300 µg three times 
a day, and 1%–44% for 600 µg three times a day, 900 µg 
three times a day and 1200 µg three times a day, respec-
tively.
Biomarkers
In patients with observed responses (defined as CR, PR or 
stable disease), the serum levels of S100B and MIA were 
sustainably low over the course of the study, whereas in 
some of the patients who had PD, there was a consider-
able increase in S100B and MIA serum levels with time. 
During treatment with pasireotide, there was a decrease 
in the serum level of growth factors (IGF-1 and IGF-2) 
and melanoma response biomarkers (MIA and S100B) 
(figure 1). Furthermore, there was a decrease in IGFBP3 
levels (online supplementary figure 3) and an increase in 
IGFBP2 serum levels with time.
Ki-67, a marker of proliferation, was assessed before 
and during pasireotide treatment in four patients. Three 
of the four tumour samples showed decreases in Ki-67 
staining following pasireotide treatment (figure 2). 
Individual patient response summary
The patient characteristics and response to treatment of 
those five patients who completed the treatment in the 
dose-escalation phase will be described in more detail, 
as they provide the most relevant information of the 
potential effect of pasireotide on patients with advanced 
melanoma. Of these five patients who completed the 
dose-escalation phase, four patients (patient numbers 
3, 4, 8 and 9) received high dose of 3600 µg pasireotide, 
Table 2 Adverse events (≥20% incidence), regardless of 
study drug relationship, by preferred term and dose level*− 
dose-escalation phase (safety set)
Preferred term
Pasireotide SC, n=10
300 µg 
tid
n (%)
600 µg 
tid
n (%)
900 µg 
tid
n (%)
1200 µg 
tid,
n (%)
All 
patients
n (%)
Diarrhoea 4 (40) 1 (10) 0 0 5 (50)
Nausea 3 (30) 2 (20) 1 (10) 0 5 (50)
Fatigue 2 (20) 0 0 0 2 (20)
Hyperglycaemia 2 (20) 0 0 0 2 (20)
Hypophosphatemia 1 (10) 1 (10) 1 (10) 0 2 (20)
Tumour pain 2 (20) 0 0 0 2 (20)
Chills 0 1 (10) 1 (10) 0 2 (20)
*List of all AEs that started at each specific dose level. A patient 
with multiple occurrence of an AE preferred term in each dose level 
is counted only once for that preferred term.
AEs, adverse events; SC, subcutaneous; tid, three times a day.
Table 3 Adverse events (≥20% incidence) regardless of 
study drug relationship by preferred term (safety set) − 
overall (dose-escalation phase+follow-up phase)
Preferred term All patients, n (%)
Diarrhoea 5 (50)
Nausea 5 (50)
Fatigue 3 (30)
Hyperglycaemia 3 (30)
Hypophosphatemia 3 (30)
Chills 2 (20)
Tumour pain 2 (20)
Weight decreased 2 (20)
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while the highest dose received by the remaining one 
patient (patient number 1) was lower with 1800 µg. The 
treatment time for the remaining patients may not have 
been long enough and/or the applied dose may not have 
been high enough in this dose-escalation study to result 
in significant responses in efficacy.
Patient number 1 was a 64-year-old Caucasian male 
diagnosed with cutaneous acral-lentiginous melanoma 
(without BRAF and NRAS mutation; stage IVa). The 
presence of three target and three non-target lesions 
were identified in this patient. This patient did not 
receive pasireotide treatment as per the dosing schedule 
Figure 1 Individual line plots for biomarkers (A) IGF-1, (B) IGF-2, (C) S100B and (D) MIA. *For patient number 2, samples 
were collected only for these biomarkers on predose day 12, and on day 1, there were no ‘on treatment’ samples for this 
patient. CR, complete response; FAS, full analysis set; MIA, melanoma-inhibitory activity; PR, partial response; UNK, unknown.
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mentioned in the study protocol as he did not receive 
more than 1800 µg and completed four cycles of treat-
ment. The patient received the first dose of pasireotide 
300 µg in the dose-escalation phase. The dose was gradu-
ally escalated up to 1800 µg as per protocol; the response 
observed was stable disease in the dose escalation phase. 
However, due to the occurrence of grade 3 diarrhoea and 
nausea, study drug was temporarily interrupted for 7 days 
and then reduced to 900 µg. The patient completed the 
dose escalation phase and was treated for another 12 days 
in the follow-up phase. The overall lesion response was 
considered as PD in the follow-up phase, which led to the 
permanent discontinuation of this patient from the study.
Patient number 3 was a 63-year-old Caucasian female 
diagnosed with BRAF-WT and NRAS-WT stage IVa cuta-
neous nodular melanoma. The presence of one target 
lesion and three non-target lesions were identified in the 
patient. This patient received pasireotide as per the dosing 
schedule mentioned in the study protocol and completed 
10 cycles of treatment with an exception of a dosing error, 
occurred during the eighth cycle. The results of CT/MRI 
scans (on days 29, 57, 113, 169 and 225) and 18-FDG-
PET (on days 29, 57, 113 and 169) revealed the presence 
of stable target lesions throughout the study. However, 
during cycle 3, worsening of the non-target lesion in the 
lung and the generation of a cutaneous lesion in the 
left upper thigh occurred, which was considered as PD. 
During cycle 4, the CT/MRI and FDG/PET scan revealed 
worsening of the non-target lesion (pulmonal noduli), 
and the response was considered as PD. The investigator 
decided not to discontinue the treatment, as the patient 
was benefitting from treatment. Further evaluations until 
the end of study revealed stable disease. This patient also 
showed significantly lower levels of S100B. At the end of 
the study, the patient was treated with compassionate use 
of pasireotide without any safety follow-up.
Patient number 4 was a 77-year-old Caucasian male 
diagnosed with BRAF-WT and NRAS-WT stage IVc cuta-
neous melanoma. The presence of five target lesions and 
two non-target lesions were identified in the patient. The 
patient received pasireotide as per the dosing schedule 
mentioned in the study protocol and completed six 
cycles of treatment. Due to the lack of efficacy, this 
patient switched to the twice-daily regimen and received 
a dose of 2400 µg pasireotide but then discontinued due 
to disease progression. CT/MRI scans and 18-FDG-PET 
results showed stable disease for target and non-target 
lesions during cycle 3 (day 30) and PD during cycle 5 
(day 58), due to worsening of the non-target lesions. On 
day 114, CT scan showed worsening of the target lesions, 
continued worsening of the non-target lesion (left deep 
lymph node) and two new lesions (at left adrenals and 
Figure 2 Effect on Ki-67 biomarker levels before and after pasireotide. For those patients with the histological data of Ki-67 
before and after treatment, n=4. Individual patient response summary; the responses (PR/stable disease/PD) are based on CT/
MRI at specific time points, corresponding to the grey bar. PD, progressive disease; PR, partial response.
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liver), and the tumour response was assessed as PD. No 
FDG-PET was performed. This patient showed signif-
icant improvement in ascites, which appeared to be 
an independent effect of the drug that considerably 
improved his quality of life. However, due to disease 
progression, he was discontinued from pasireotide treat-
ment and prescribed with paclitaxel in a therapeutic 
setting (after 7 days of the last study drug dose). After 
discontinuation, the ascites recurred, and pasireotide 
was readministered that led to a significant reduction in 
weight (from 85 kg to 63 kg) and improvement in ascites 
(from grade 2 to grade 1). This patient also showed 
significantly increased serum levels of S100B and MIA 
with respect to time.
Patient number 8 was a 72-year-old Caucasian male diag-
nosed with BRAF-WT and NRAS-WT stage IVa cutaneous 
melanoma and had six target lesions and no non-target 
lesions. This patient received pasireotide treatment as per 
the dosing schedule mentioned in the study protocol and 
completed eight cycles of treatment. During all the eval-
uations from cycles 1 to 8, the tumour response for this 
patient was considered as stable disease by CT/MRI (on 
days 29, 57, 85 and 114) and FDG/PET (on days 29 and 
57), and no new lesions were observed. The patient also 
showed low S100B and MIA serum levels throughout the 
study. This patient completed treatment and was further 
enrolled on the rollover study CSOM230B2412.
Patient number 9 was a 67-year-old Caucasian male 
diagnosed with BRAF-WT and NRAS-WT stage IV mela-
noma, identified with the presence of one target lesion 
and one non-target lesion. The patient received pasir-
eotide as per the dosing schedule of the study protocol 
and completed eight cycles of treatment. No new target 
lesions were observed during the tumour assessment. 
CT/MRI (on days 57 and 114) and FDG/PET scans (on 
days 29 and 60) assessed the tumour response as PR. This 
patient also showed low levels of S100B and MIA serum 
levels during the study. The patient completed treatment 
and enrolled in the rollover study CSOM230B2412.
dIsCussIon
This is the first study to demonstrate that pasireotide is 
safe and well tolerated in patients with BRAF-WT and 
NRAS-WT melanoma. The safety profile of pasireotide 
was consistent to that previously reported in other indica-
tions with the exception of a lower incidence of hypergly-
cemia, observed in this patient population.23–25 A PR and 
stable disease that were observed in this study comprising 
a small sample size (n=10) suggest further investigation 
should be conducted. Of note, patients enrolled in this 
study had significant disease burden (stage IIIC and IV 
melanoma) and seven patients discontinued treatment 
prematurely (five patients discontinued in the dose-esca-
lation phase and two in the treatment follow-up phase). 
Most of those who discontinued earlier were not treated 
for long and did not reach high doses. Six of them 
discontinued due to disease progression (four PDs in the 
dose-escalation phase and two in the treatment follow-up 
phase).
MAPK and PI3K pathways are the major signalling path-
ways in melanoma, which regulate cell growth, prolifera-
tion, survival and transformation. These pathways may be 
activated by the IGF-1 signalling via IGF-1R. Additionally, 
MAPK pathway may be activated in melanoma directly 
via activating mutations in the signalling components 
including NRAS, BRAF, MEK 1/2 and c-KIT mutations 
or via mutations in the tumour suppressor genes like 
NF-1. IGFRs are overexpressed in human melanoma cells, 
and the IGF-1 signalling pathway via IGF-1R is shown to 
play a key role in melanoma progression.14 15 Due to the 
well-established inhibitory effect of pasireotide on GH/
and IGF-1, which was also observed for patients with mela-
noma in the current study, there may be an opportunity 
for combining pasireotide with other anticancer agents 
targeting different oncogenic pathways in melanoma. KIT 
inhibitors have shown some efficacy in a subset of patients 
with BRAF-WT and NRAS-WT melanoma harbouring KIT 
mutations, particularly those with exon 11 or 13 muta-
tions.26 However, this therapeutic option will be appli-
cable only to the 10%–22% of patients with KIT mutant 
BRAF-WT and NRAS-WT melanoma.4 5
In the present study, the antisecretory effect of pasi-
reotide was confirmed by decreased serum levels of 
IGF-1 and IGF-2 and a corresponding decrease in 
IGFBP3 levels (independent of response). Pasireotide 
is believed to decrease IGF-1 levels primarily through its 
ability to decrease GH secretion in the pituitary gland, 
thereby decreasing the synthesis of IGF-1 in the liver.27 
The observed suppression of IGF-2 levels suggests that 
pasireotide regulates autocrine/paracrine growth signals 
in the tumour, since IGF-2 is also known to be secreted 
by tumours and surrounding cells.28 IGFBP3 is the major 
carrier of the IGF ligands and is also responsive to GH. 
The decrease in IGFBP3 provides additional evidence that 
pasireotide had an antisecretory effect. IGFBP2 serum 
level was increased after the treatment with pasireotide, 
which is supported by similar results observed in patients 
with acromegaly.17 Additionally, there was a decrease in 
the serum level of melanoma response biomarkers (S100B 
and MIA) in patients who had response (defined as PR, 
CR and stable disease), whereas patients with disease 
progression had high S100B and MIA serum levels. These 
results are supported by the observation that disease 
progression is directly proportional to the elevated S100B 
and MIA.29 30
Possible limitations of this study include the following: 
insufficient study drug exposure as patients were drop-
ping out during the dose-escalation phase due to disease 
progression. Some patients received a lower dose for a 
shorter period of time and disease progression occurred 
early. Nevertheless, the patients who continued to the 
follow-up phase received high doses of pasireotide for 
more than 5 months and showed stable disease/PR 
or stable disease in target lesions. Further prospective 
randomised studies are warranted to evaluate the efficacy 
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of pasireotide in BRAF-WT and NRAS-WT melanoma. 
Pasireotide may also be potentially used in combination 
with other therapeutic agents in the treatment of patients 
with BRAF-WT and NRAS-WT melanoma.
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